A Safety Study Assessing Oral Anticoagulation With Apixaban Versus Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD) on Chronic Hemodialysis Treatment

Trial Profile

A Safety Study Assessing Oral Anticoagulation With Apixaban Versus Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD) on Chronic Hemodialysis Treatment

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs Apixaban (Primary) ; Phenprocoumon
  • Indications Atrial fibrillation; Renal failure; Stroke
  • Focus Therapeutic Use
  • Acronyms AXADIA
  • Most Recent Events

    • 05 Apr 2017 Planned End Date changed from 1 Feb 2019 to 1 Apr 2019.
    • 05 Apr 2017 Planned primary completion date changed from 1 Jul 2018 to 1 Sep 2018.
    • 05 Apr 2017 Planned initiation date changed from 1 Jan 2017 to 1 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top